CUSIP: 14757U109
What is CUSIP 14757U109?
CUSIP 14757U109 identifies CASI - CASI PHARMACEUTICALS INC - COM in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Open recent reporting periods for CUSIP 14757U109:
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2023 Q1 | 0 | $0 | -$629,139 | 0 | |
| 2022 Q4 | 351,474 | $629,139 | -$21,637 | $1.79 | 3 |
| 2022 Q3 | 363,562 | $945,000 | +$12,977 | $2.60 | 2 |
| 2022 Q2 | 358,567 | $1,026,000 | -$25,213,191 | $2.86 | 2 |
| 2022 Q1 | 23,306,553 | $18,884,089 | -$3,721,274 | $0.81 | 36 |
| 2021 Q4 | 27,963,285 | $22,368,076 | -$3,392,072 | $0.80 | 46 |
| 2021 Q3 | 38,670,498 | $46,019,210 | -$9,795,208 | $1.19 | 55 |
| 2021 Q2 | 46,671,130 | $72,329,878 | -$13,539,472 | $1.55 | 65 |
| 2021 Q1 | 53,077,474 | $127,388,870 | +$27,900,830 | $2.40 | 80 |
| 2020 Q4 | 41,424,694 | $122,202,721 | +$5,597,299 | $2.95 | 68 |
| 2020 Q3 | 39,599,236 | $60,588,863 | +$25,462,661 | $1.53 | 64 |
| 2020 Q2 | 22,878,667 | $57,193,612 | +$2,915,666 | $2.50 | 56 |
| 2020 Q1 | 21,739,166 | $44,345,565 | +$2,549,424 | $2.04 | 55 |
| 2019 Q4 | 20,437,523 | $63,151,654 | +$4,853,188 | $3.09 | 49 |
| 2019 Q3 | 10,894,078 | $36,384,713 | -$2,370,012 | $3.34 | 50 |
| 2019 Q2 | 11,652,206 | $37,283,720 | +$1,402,976 | $3.20 | 48 |
| 2019 Q1 | 11,475,709 | $32,933,759 | -$53,260 | $2.87 | 51 |
| 2018 Q4 | 11,417,745 | $45,896,953 | +$2,570,804 | $4.02 | 50 |
| 2018 Q3 | 10,748,223 | $50,195,309 | +$4,023,678 | $4.67 | 56 |
| 2018 Q2 | 9,816,931 | $80,787,402 | +$41,718,111 | $8.23 | 52 |
| 2018 Q1 | 4,970,323 | $20,728,000 | +$5,675,403 | $4.17 | 36 |
| 2017 Q4 | 3,623,662 | $11,777,000 | +$4,073,224 | $3.25 | 30 |
| 2017 Q3 | 2,388,403 | $4,231,000 | +$186,322 | $1.77 | 19 |
| 2017 Q2 | 2,297,879 | $2,413,000 | -$60,889 | $1.05 | 18 |
| 2017 Q1 | 2,341,993 | $3,324,000 | +$578,948 | $1.42 | 17 |
| 2016 Q4 | 2,217,476 | $2,549,000 | +$20,507 | $1.15 | 20 |
| 2016 Q3 | 2,206,008 | $2,448,000 | +$18,682 | $1.11 | 23 |
| 2016 Q2 | 2,185,988 | $2,561,000 | +$35,327 | $1.17 | 21 |
| 2016 Q1 | 2,157,351 | $2,286,000 | +$167,329 | $1.06 | 20 |
| 2015 Q4 | 2,001,529 | $1,921,000 | -$419,303 | $0.96 | 20 |
| 2015 Q3 | 2,423,573 | $2,592,000 | +$303,481 | $1.07 | 23 |
| 2015 Q2 | 2,139,560 | $3,834,233 | -$34,339 | $1.79 | 21 |
| 2015 Q1 | 2,159,630 | $3,206,192 | -$1,106,947 | $1.48 | 21 |
| 2014 Q4 | 2,993,802 | $4,027,053 | -$304,187 | $1.33 | 23 |
| 2014 Q3 | 3,215,798 | $5,760,072 | +$2,689,171 | $1.79 | 21 |
| 2014 Q2 | 1,715,400 | $3,087,000 | +$3,087,000 | $1.80 | 5 |